Background Coronavirus disease 2019 (COVID-19) is a newly emerging pandemic that affected millions of people worldwide caused by novel coronavirus SARS-CoV-2. The first cases reported suffered from respiratory symptoms. Main body Various extrapulmonary manifestations were linked to COVID-19 in several reports including cardiovascular, genitourinary, gastrointestinal, and skin. It is important that every clinician should be aware of these non-respiratory manifestations for early diagnosis and prompt management. This review aims to summarize the different extrapulmonary manifestations of COVID-19 disease and highlight the importance of multidisciplinary care. Conclusion COVID-19 is a disease of multi-organ involvement. Manifestations may vary depending on which organ is involved.

Background Cardiovascular system involvement in coronavirus disease-2019 (COVID-19) has gained great interest in the scientific community. Main body Several studies reported increased morbidity and mortality among COVID-19 patients who had comorbidities, especially cardiovascular diseases like hypertension and acute coronary syndrome (ACS). COVID-19 may be associated with cardiovascular complications as arrhythmia, myocarditis, and thromboembolic events. We aimed to illustrate the interactions of COVID-19 disease and the cardiovascular system and the consequences on clinical decision as well as public health. Conclusions COVID-19 has negative consequences on the cardiovascular system. A high index of suspicion should be present to avoid poor prognosis of those presenting with unusual presentation.

No abstract

Background: Liver cirrhosis, the 11 th death common cause, is a severe disorder that includes inflammation, oxidative damage, also immune response. Harmaline shows the antioxidant and anti-inflammatory mechanisms that aid in partial protection of hepatic cirrhosis.Objective: This work aimed to evaluate the protection effect of harmaline against liver cirrhosis induced by thioacetamide in mice via arginase-1 enzyme activity modulation.Methods: The study was carried out on forty male mice divided into four groups. Control group (GI), thioacetamide group (GII), harmaline group (GIII), and co-treated group (GIV). By the end of the experiment, arginase-1 activity and liver enzymes were measured in serum and liver tissue.Results: The results showed that combined harmaline administration can cause significant suppression of liver inflammation by increasing ariginase-1 activity to nearly normal values. Inhibition of activated myofibroblasts cells and extracellular matrix accumulation was also noticed. Conclusion:Harmaline has protective role against liver cirrhosis induced by thioacetamide in mice. It can be therapeutically used as a safe liver support after further in vivo studies.

No abstract